LOW-VOLUME · FEMALE-LED
eluxadoline Side Effects
eluxadoline (also sold as Viberzi) is a LOW-VOLUME FAERS extract #434 of 524 by FAERS report count. Still opens on FEMALE-LED: 76% of sex-coded reports are female (1,984 F / 638 M).
Data updated 2026-05-15
- 2,870
- FAERS reports
Thinner FAERS book - still a temporal association ledger, not proof of cause. Methodology.
eluxadoline reporting skew - 76% of sex-coded reports are female (1,984 F / 638 M). Volume band LOW-VOLUME #434 of 524 by FAERS report count; caseload SIGNAL.
Thinner FAERS extract for eluxadoline (Viberzi) (2,870 reports #434 of 524 by FAERS report count). 76% of sex-coded reports are female (1,984 F / 638 M). Sparse books still carry named reaction rows when present; not medical advice.
Counts from the openFDA FAERS extract (2012–2025). Stamps SIGNAL · DEATH-MARKED · HOSP-MID · FEMALE-LED.
ABDOMINAL PAIN leads 348 of 2,870 reports
FEMALE-LED reporters · age peak 45-64
Female-led reporters (76% of sex-coded rows)
Age peak 45-64 (428 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death appears on 63 reports (2.2% - MARKED). Reactions below co-occur in those rows only.
| Reaction | Reports |
|---|---|
| DEATH | 37 |
| COMPLETED SUICIDE | 9 |
| VOMITING | 5 |
| CARDIAC ARREST | 4 |
| DIARRHOEA | 4 |
| LETHARGY | 4 |
| PANCREATITIS | 4 |
| SUSPECTED SUICIDE | 4 |
| ABDOMINAL PAIN | 3 |
| ABDOMINAL PAIN UPPER | 3 |
| ACUTE KIDNEY INJURY | 3 |
| HEART RATE INCREASED | 3 |
| NAUSEA | 3 |
| RENAL FAILURE | 3 |
| RESPIRATORY FAILURE | 3 |
| UNEVALUABLE EVENT | 3 |
| ABDOMINAL DISTENSION | 2 |
| ASCITES | 2 |
| BLOOD PRESSURE DECREASED | 2 |
Reactions in Hospitalization Reports
Hospitalization mid-share (546, 19.0%). Co-reported reactions:
| Reaction | Reports |
|---|---|
| PANCREATITIS | 148 |
| PANCREATITIS ACUTE | 64 |
| ABDOMINAL PAIN | 63 |
| DIARRHOEA | 46 |
| VOMITING | 41 |
| SPHINCTER OF ODDI DYSFUNCTION | 39 |
| NAUSEA | 30 |
| PAIN | 28 |
| CONSTIPATION | 27 |
| ABDOMINAL PAIN UPPER | 26 |
| DEHYDRATION | 23 |
| FALL | 23 |
| FATIGUE | 23 |
| PNEUMONIA | 23 |
| DYSPNOEA | 22 |
| CHEST PAIN | 19 |
| WEIGHT DECREASED | 19 |
| CONTRAINDICATED PRODUCT ADMINISTERED | 17 |
| DIZZINESS | 15 |
How to read eluxadoline FAERS figures (SIGNAL · DEATH-MARKED · HOSP-MID)
FAERS holds 2,870 voluntary reports linked to eluxadoline (Viberzi), 2012-2025. Death is listed on 63 (2.2%). Hospitalization appears on 546 (19.0%). Top co-reported indication: Irritable Bowel Syndrome.
Sparse extract - named reactions and FEMALE-LED skew still differ by drug; not a complete safety profile.
Read with eluxadoline
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-MARKED · HOSP-MID stamps.
ABS(total_reports) peer at 2,845 FAERS cases (Δ 25 lighter vs eluxadoline); DEATH-HEAVY · HOSP-LIGHT · SEX-BALANCED vs this page's SIGNAL · DEATH-MARKED · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 2,896 FAERS cases (Δ 26 heavier vs eluxadoline); DEATH-HEAVY · HOSP-MID · SEX-BALANCED vs this page's SIGNAL · DEATH-MARKED · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 2,902 FAERS cases (Δ 32 heavier vs eluxadoline); DEATH-HEAVY · HOSP-MID · FEMALE-LED vs this page's SIGNAL · DEATH-MARKED · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 2,824 FAERS cases (Δ 46 lighter vs eluxadoline); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's SIGNAL · DEATH-MARKED · HOSP-MID · FEMALE-LED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 59.9 pp vs eluxadoline's DEATH-MARKED): CASELOAD · HOSP-MID.
eluxadoline stamps SIGNAL · FEMALE-LED; class peers and methodology beat restating the same FAERS caveats on every effects URL.